November 27, 2025 a 01:00 pm
DXCM: Fundamental Ratio Analysis - DexCom, Inc.
DexCom, Inc. offers promising opportunities with its continuous glucose monitoring systems which are crucial for diabetes management. Backed by strong collaborations and innovative product lines like DexCom G7, the company stands as a strong player in the medical device market, poised for growth amid rising diabetes prevalence globally.
Fundamental Rating
The fundamental data illustrates a balanced performance with robust returns juxtaposed with higher debt levels.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4/5 | |
| Return on Equity | 5/5 | |
| Return on Assets | 5/5 | |
| Debt to Equity | 1/5 | |
| Price to Earnings | 1/5 | |
| Price to Book | 1/5 |
Historical Rating
The historical scores indicate stable fundamentals over time.
| Date | Overall Score | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-11-26 | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
| Previous | 0 | 4 | 5 | 5 | 1 | 1 | 1 |
Analyst Price Targets
Analyst estimates show optimism with a median target portraying potential upside.
| High | Low | Median | Consensus |
|---|---|---|---|
| $99 | $63 | $84 | $83.89 |
Analyst Sentiment
Market participants show a positive bias with a predominant Buy recommendation.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 40 | |
| Hold | 10 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
DexCom, Inc. presents a compelling investment opportunity with an innovative product suite and strategic partnerships aiding expansion and market penetration. However, potential investors should remain cautious due to the financial leverage and valuation concerns reflected in fundamental scores. The overall positive analyst sentiment and price targets offer a bullish outlook, suggesting opportunities for growth. Balancing these factors is key for potential investors considering DexCom, Inc. in their portfolio.